A Prospective Study of the Relationship Between Clinical Outcomes After Enzalutamide and Serum Androgen Levels Measured via Liquid Chromatography-tandem Mass Spectrometry in Patients with Castration-resistant Prostate Cancer

BACKGROUND: Enzalutamide (ENZ) is used to treat patients with castration-resistant prostate cancer (CRPC). However, the kinetics of serum androgens before and after ENZ treatment are unknown. OBJECTIVE: To elucidate the kinetics of serum androgens and explore the possibility of identifying a useful...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyazawa, Yoshiyuki, Sekine, Yoshitaka, Arai, Seiji, Nakamura, Toshiyuki, Takezawa, Yutaka, Shimizu, Nobuaki, Matsuo, Yasushige, Ogura, Haruyuki, Takei, Tomoyuki, Suzuki, Kazuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Prostate Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317787/
https://www.ncbi.nlm.nih.gov/pubmed/34337535
http://dx.doi.org/10.1016/j.euros.2021.05.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317787/
https://www.ncbi.nlm.nih.gov/pubmed/34337535
http://dx.doi.org/10.1016/j.euros.2021.05.003

Ejemplares similares